Open Access Articles- Top Results for JWH-133


Systematic (IUPAC) name
(6aR,10aR)-3-(1,1-Dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H-dibenzo[b,d]pyran
Clinical data
259869-55-1 7pxN
PubChem CID 6918505
IUPHAR ligand 747
ChemSpider 5293702 7pxY
ChEMBL CHEMBL371214 7pxY
Chemical data
Formula C22H32O
312.489 g/mol
 14pxN (what is this?)  (verify)

JWH-133 is a potent selective CB2 receptor agonist with a Ki of 3.4nM and selectivity of around 200x for CB2 over CB1 receptors. It was discovered by and named after, John W. Huffman.

JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers[citation needed]. This anti-inflamatory action is induced through agonist action at cannabinoid receptors, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.

It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in Madrid. [1]

Legal Status

The substance commonly referred to as "JWH-133" is not a scheduled substance in the U.S[citation needed]. Low abuse potential makes it less likely for regulation relative to its sister drugs such as JWH-018, as JWH-133 is selective for the non-psychoactive CB2 receptor and thus lacks significant psychoactive effects.[2]


  1. ^
  2. ^

External links

  • Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation Also has been shown to block grown of tumors. More clinical studies and trials are needed.